{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:01:46Z","timestamp":1789776106390,"version":"4.0.1"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>EAU guidelines advise patients with intermediate risk Gleason 4+3=7 prostate cancer undergo cross-sectional abdominopelvic imaging and bone scan for metastatic screening. We hypothesised detection rate of extra-prostatic disease in this cohort is low using conventional CT\/bone scans and could potentially be avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Patients with overall Gleason 4+3 histology were identified over 69 months at East Kent University Hospitals NHS Trust. Patients were excluded if PSA &gt;20ng\/mL and\/or MRI prostate &gt;T3b stage. Primary outcomes were: (a) detection rates of metastatic disease using conventional CT and bone scan and b) the proportion of fully-staged patients with positive lymph nodes at dissection or biochemical recurrence following robotic-assisted laparoscopic prostatectomy (RALP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 134 patients were identified. Median age was 72 (range 45\u201383), PSA 7.8ng\/mL (range 1.8\u201319.3) and prostate volume 40cc (range 10\u2013129). 130\/134(97%) had MRI scans prior to staging. 124\/134(93%) had bone scans and 83\/134(62%) had CT scans, of which 77\/134(57%) had both. 0\/124(0%) bone scans identified metastatic disease and only 2\/83(2%) CT scans identified nodal disease not detected by MRI. 0\/134(0%) had management changes from staging. 57\/134(43%) patients negatively-staged proceeded to RALP. 19\/57(32%) had lymph node dissections. 6(11%) had missed metastatic disease at 19 months median follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Detection of metastatic disease by conventional CT and bone scan was poor in this cohort, despite their presence, and their recommendation by EAU seems unwarranted. Patients could safely avoid these scans and proceed directly to radical treatment, due to the theoretical benefit of treating despite oligometastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jcas-2025-0006","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:10:29Z","timestamp":1789773029000},"page":"24-28","source":"Crossref","is-referenced-by-count":0,"title":["A Farewell to Arms - An Institutional Review of Conventional Staging for Intermediate-Risk Prostate Cancer"],"prefix":"10.2478","volume":"11","author":[{"given":"Rustam","family":"Karanjia","sequence":"first","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Sarkar","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Basavaraju","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwabunmi","family":"Tayo","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sashi","family":"Kommu","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humayun","family":"Bashir","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Streeter","sequence":"additional","affiliation":[{"name":"East Kent Hospitals University NHS Trust: East Kent Hospitals University NHS Foundation Trust Canterbury , Kent UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2026091823102051009_j_jcas-2025-0006_ref_001","unstructured":"Prostate Cancer - INTRODUCTION - Uroweb [Internet]. [cited 2023 Oct 3]. Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_002","doi-asserted-by":"crossref","unstructured":"Ayyathurai R, Mahapatra R, Rajasundaram R, Srinivasan V, Archard NP, Toussi H. A study on staging bone scans in newly diagnosed prostate cancer. Urol Int [Internet]. 2006 Apr [cited 2023 Oct 4];76(3):209\u201312. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16601380\/","DOI":"10.1159\/000091620"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_003","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int [Internet]. 2003 Nov [cited 2023 Oct 4];92(7):685\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14616446\/","DOI":"10.1046\/j.1464-410X.2003.04480.x"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_004","doi-asserted-by":"crossref","unstructured":"Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol [Internet]. 2012 [cited 2023 Oct 3];61(6):1132\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22099610\/","DOI":"10.1016\/j.eururo.2011.11.008"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_005","doi-asserted-by":"crossref","unstructured":"Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: A summary of the literature. Journal of Urology [Internet]. 2004 [cited 2023 Oct 3];171(6 I):2122\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15126770\/","DOI":"10.1097\/01.ju.0000123981.03084.06"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_006","unstructured":"Prostate cancer | Topic | NICE [Internet]. [cited 2023 Oct 8]. Available from: https:\/\/www.nice.org.uk\/guidance\/conditions-and-diseases\/cancer\/prostate-cancer"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_007","unstructured":"Whiting D, Giona S, Yao M, Hassan R, Doan H, Karanjia R, et al. Are staging bone scans necessary in patients with T3a prostate cancer? A multicentre study. https:\/\/doi.org\/101177\/20514158221137110 [Internet]. 2022 Nov 23 [cited 2023 Oct 4]; Available from: https:\/\/journals.sagepub.com\/doi\/abs\/10.1177\/20514158221137110"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_008","doi-asserted-by":"crossref","unstructured":"Grant Owens R, Loloi J, Lehman EB, Kaag MG, Raman JD, Merrill SB. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer? Urologic Oncology: Seminars and Original Investigations. 2021 Jul 1;39(7):433.e9\u2013433.e15.","DOI":"10.1016\/j.urolonc.2021.01.029"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_009","doi-asserted-by":"crossref","unstructured":"Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. 68Ga-PSMA Positron Emission Tomography\/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol [Internet]. 2016 Oct 1 [cited 2023 Oct 4];70(4):553\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26810345\/","DOI":"10.1016\/j.eururo.2015.12.051"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_010","doi-asserted-by":"crossref","unstructured":"Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol [Internet]. 2016 May 1 [cited 2023 Oct 4];195(5):1436\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26682756\/","DOI":"10.1016\/j.juro.2015.12.025"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_011","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet [Internet]. 2020 Apr 11 [cited 2023 Oct 3];395(10231):1208\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32209449\/"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_012","doi-asserted-by":"crossref","unstructured":"Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol [Internet]. 2019 Apr 1 [cited 2023 Oct 4];75(4):659\u201366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29625755\/","DOI":"10.1016\/j.eururo.2018.03.013"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_013","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw [Internet]. 2022 Dec 1 [cited 2024 May 8];20(12):1288\u201398. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36509074\/"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_014","doi-asserted-by":"crossref","unstructured":"Jochumsen MR, Bouchelouche K. PSMA PET\/CT for Primary Staging of Prostate Cancer - An Updated Overview. Semin Nucl Med [Internet]. 2024 Jan 1 [cited 2024 May 8];54(1):39\u201345. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37487824\/","DOI":"10.1053\/j.semnuclmed.2023.07.001"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_015","unstructured":"EAU 2024: Update on PSMA PET\/CT: When Does Its Use in Staging Have an Impact on Survival? [Internet]. [cited 2024 May 8]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/eau-2024\/eau-2024-prostate-cancer\/150959-eau-2024-update-on-psma-pet-ct-when-does-its-use-in-staging-have-an-impact-on-survival.html"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_016","doi-asserted-by":"crossref","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, DeBruycker A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol [Internet]. 2018 Feb 10 [cited 2023 Oct 4];36(5):446\u201353. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29240541\/","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"2026091823102051009_j_jcas-2025-0006_ref_017","doi-asserted-by":"crossref","unstructured":"Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol [Internet]. 2018 Oct 1 [cited 2023 Oct 4];74(4):455\u201362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30227924\/","DOI":"10.1016\/j.eururo.2018.06.004"}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jcas-2025-0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:10:35Z","timestamp":1789773035000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jcas-2025-0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/jcas-2025-0006"],"URL":"https:\/\/doi.org\/10.2478\/jcas-2025-0006","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}